High-Performance Liquid Chromatography Studies to Estimate Ergosterol Content at Different Developmental Stages of the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes)
- PMID: 28094749
- DOI: 10.1615/IntJMedMushrooms.v18.i12.60
High-Performance Liquid Chromatography Studies to Estimate Ergosterol Content at Different Developmental Stages of the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes)
Abstract
Ganoderma lucidum has been widely used as a source of potent nutraceutical products. This study was planned to identify and characterize the role of ergosterol in the developmental process of G. lucidum. Four strains of G. lucidum (GL-I-IV) showed a gradual increase in biomass (from 25.52 to 31.72 g) after 3 weeks of growth in mushroom complete medium broth, with maximum biomass observed for strain GL-III. Upon cultivation of G. lucidum strains on wheat straw supplemented with 5% wheat bran, maximum biological efficiency was recorded for the GL-I strain (31.23%), followed by GL-II (26.73%); the number of fruiting bodies were 927 and 693, each weighing 33.7 and 38.6 g, respectively. The amount of ergosterol in the Ganoderma test strains varied among the strains and at different developmental stages, namely, the vegetative mycelium, spawn run, pinhead, and fruiting body phases. The maximum ergosterol content was produced by the GL-I strain during the vegetative mycelium (4601 p.g/g) and reproductive fruiting body (7009 p.g/g) stages. However, strain GL-IV followed by strain GL-II exhibited maximum ergosterol content in the spawn run stage. The ergosterol content was better for GL-II at the pinhead stage. This report indicates that ergosterol content varies among the test strains. Moreover, it increases with each stage of the cultivation process, that is, from spawn run to pinhead to and fruiting body formation.
Similar articles
-
Profiling of Intra- and Extracellular Enzymes Involved in Fructification of the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes).Int J Med Mushrooms. 2018;20(12):1209-1221. doi: 10.1615/IntJMedMushrooms.2018028898. Int J Med Mushrooms. 2018. PMID: 30806301
-
Genoprotective Capacity of Alternatively Cultivated Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), Basidiocarps.Int J Med Mushrooms. 2016;18(12):1061-1069. doi: 10.1615/IntJMedMushrooms.v18.i12.10. Int J Med Mushrooms. 2016. PMID: 28094744
-
Paddy straw as a substrate for the cultivation of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum (W.Curt.:Fr.) P. Karst. in India.Int J Med Mushrooms. 2011;13(4):397-400. doi: 10.1615/intjmedmushr.v13.i4.100. Int J Med Mushrooms. 2011. PMID: 22164770
-
Strategies to Increase the Production of Triterpene Acids in Ligzhi or Reishi Medicinal Mushroom (Ganoderma lucidum, Agaricomycetes): A Review.Int J Med Mushrooms. 2024;26(5):25-41. doi: 10.1615/IntJMedMushrooms.2024052871. Int J Med Mushrooms. 2024. PMID: 38780421 Review.
-
The Efficacy and Toxicity of Using the Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), and Its Products in Chemotherapy (Review).Int J Med Mushrooms. 2017;19(10):861-877. doi: 10.1615/IntJMedMushrooms.2017024537. Int J Med Mushrooms. 2017. PMID: 29256841 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources